Xortx Therapeutics Inc
(XRTX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 05-2003 | |
| Cash Flows From Operating Activities | |
| Net Income | 13,895 |
| Depreciation Amortization | 2,324 |
| Income taxes - deferred | 93 |
| Accounts receivable | 6,786 |
| Accounts payable and accrued liabilities | -10,896 |
| Other Working Capital | -743 |
| Other Operating Activity | 5,649 |
| Operating Cash Flow | $17,108 |
| Cash Flows From Investing Activities | |
| PPE Investments | -2,349 |
| Net Acquisitions | -325 |
| Investing Cash Flow | $-2,674 |
| Cash Flows From Financing Activities | |
| Debt Repayment | -12,613 |
| Financing Cash Flow | $-12,613 |
| Beginning Cash Position | 455 |
| End Cash Position | 1,370 |
| Net Cash Flow | $915 |
| Free Cash Flow | |
| Operating Cash Flow | 17,108 |
| Capital Expenditure | -2,349 |
| Free Cash Flow | 14,759 |